Understand drug prices
When will a generic be available?
If you take an expensive brand-name drug, one of the most common questions is simply: when will there be a cheaper generic? The answer depends on a mix of patents, FDA exclusivity periods, legal challenges and business decisions. A date that looks certain can move by months or years. This guide explains the pieces so you can make sense of the dates you see.
Key takeaways
- Generics can launch only after the brand's relevant patents and FDA exclusivity periods expire or are overcome.
- FDA exclusivity is separate from patents: 5 years for a new chemical entity, 7 years for an orphan drug, plus 6 months for pediatric studies.
- The first generic company to challenge a patent may get 180 days of exclusivity.
- The Orange Book lists the patents and exclusivities the FDA has recorded for each brand drug.
- Patent challenges and settlements often set the real launch date.
- FDA approval of a generic does not always mean it is on pharmacy shelves.
Two kinds of protection: patents and exclusivity
Patents
A patent is granted by the US Patent and Trademark Office and usually lasts 20 years from the date the application was filed. Because companies often file patents long before a drug is approved, the time left on a patent when the drug launches is usually much shorter. The law allows some of the time lost during FDA review to be restored through a patent term extension, within limits.
A single drug can be covered by many patents: on the active ingredient itself, on a particular formulation, on a method of using the drug to treat a condition, and sometimes on a delivery device. The first patent to expire is not always the one that matters most.
FDA exclusivity
Exclusivity is a period, granted by the FDA when a drug is approved, during which certain competing applications cannot be approved (or in some cases, submitted). The main types are:
| Type | Length | What it covers |
|---|---|---|
| New chemical entity (NCE) | 5 years | A drug with an active ingredient never before approved |
| New clinical investigation | 3 years | Certain changes, such as a new use or form, backed by new clinical studies |
| Orphan drug | 7 years | A drug approved for a rare disease, for that use |
| Pediatric | 6 months, added on | Added to existing patents and exclusivity when the company completes requested studies in children |
| First generic (180-day) | 180 days | The first generic company to challenge a patent, during which later generics cannot be approved |
Biologic drugs, such as many injectables made from living cells, follow a separate system: competing biosimilars cannot be approved until 12 years after the original biologic's approval, and patents still apply on top of that.
The Orange Book
The FDA's Orange Book lists approved drugs along with the patents and exclusivities that apply to them. Brand companies must list patents that cover the drug substance, the drug product (formulation) or approved methods of use. Each entry includes the patent's expiration date.
The Orange Book is a good starting point, but it has limits. It does not list every patent that might matter, and it does not tell you about lawsuits, settlements or business plans. FairPill shows Orange Book patents and exclusivities on drug pages, and our upcoming generics page brings together drugs where protection is due to end.
How generics challenge patents
A company that wants to sell a generic files an Abbreviated New Drug Application (ANDA) with the FDA. For each patent listed in the Orange Book, it must say whether it will wait for the patent to expire or argue that the patent is invalid or would not be infringed by its product. That second option is called a Paragraph IV certification.
A Paragraph IV certification often leads to a lawsuit. If the brand company sues within the time allowed, FDA approval of the generic is generally put on hold for up to 30 months while the case proceeds, unless the court rules sooner. The first company to file a Paragraph IV challenge may earn the 180-day first-generic exclusivity if it wins or settles and launches.
Settlements
Many patent cases end in a settlement rather than a court ruling. Settlements commonly set an agreed date on which the generic company may launch, sometimes years before the last patent expires. These dates are often reported publicly but may not appear in the Orange Book. Federal regulators review some settlements to check that they do not unfairly delay competition.
Why generic dates move
A projected launch date can change for many reasons:
- A court decision invalidates a patent, or upholds it.
- A settlement sets a new entry date.
- Pediatric exclusivity adds six months.
- New patents are listed, or old ones are removed.
- The first-filer's 180-day exclusivity is delayed or forfeited, holding up other generics.
- A generic company has manufacturing or approval problems.
- A company launches "at risk" before litigation is finished, or decides not to launch at all.
The FDA may also grant tentative approval: the generic meets the scientific standards, but final approval must wait for patents or exclusivity. A tentative approval is a good sign, but not a launch date.
Even after launch, savings can arrive gradually. When only the first generic and perhaps an authorized generic are on the market, prices often stay relatively high. Prices tend to fall further once more manufacturers join. You can follow that on our price changes page.
How to track when your generic may arrive
- Look up your brand drug on FairPill and check its Orange Book patents and exclusivities.
- Check the upcoming generics page for expected timing.
- Set up an alert so you hear when a generic appears in the pricing data.
- Ask your pharmacist whether they have heard of a generic launch for your medicine.
- When a generic launches, ask your prescriber or pharmacist whether it is suitable for you, and compare prices.
- Until then, look at manufacturer savings programs and other options to lower your costs.
While you wait
If a generic is still years away, there may be other ways to save. Your prescriber may know of a different medicine in the same class that already has a generic, though whether that is suitable is their decision. For people on Medicare, some high-cost brands now have negotiated prices - see Medicare drug price negotiation explained. Our guide to paying less for prescriptions covers manufacturer programs and patient assistance.
Free toolIs my drug price fair? Check any quoteWhen a new generic does arrive, early cash prices can vary a lot between pharmacies. If you are one of the first to fill it, please share what you paid so others know what to expect.
This guide is general information, not medical or financial advice. Talk to your pharmacist or prescriber about your own medicines.
Questions about this guide
No comments yet. Questions, tips, what worked for you - start the conversation.